Study finds link from ESAs to leukemia

In another blow to anemia drugs, Mayo Clinic researchers announced today that erythropoiesis-stimulating agents--like Amgen's Aranesp and Epogen, and Johnson & Johnson's Procrit--may cause patients with a bone-marrow disorder to develop leukemia.

The researchers had been studying the risk factors for progression from primary myelofibrosis to leukemia, and in the process uncovered this link to ESAs. Though the lead investigator said the study results need to be validated in other trials, he also said that the findings should be taken into account when doctors and patients are deciding whether to use the drugs.

- check out this release

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.